PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Oth...(slightly lower tax rate is expected to a...)

Date:9/26/2007

slightly lower tax rate is expected to add approximately one cent to diluted earnings per share projections in the current quarter and approximately four to six cents per diluted share for Fiscal Year 2008. The Company anticipates that these increases in diluted earnings per share will be offset by the negative impact of the non-cash amortization of intangibles related to the APEX acquisition. Previously issued diluted earnings per share guidance was in the range of $0.32 to $0.34 for the first quarter and in the range of $1.56 to $1.66 for the Fiscal Year.

A conference call to discuss PAREXEL's acquisition of APEX and updated financial outlook will begin at 10:00 a.m. EDT tomorrow, Thursday, September 27th and will be broadcast live over the Internet via webcast. The webcast may be accessed in the "Webcasts" portion of the Investor Relations section of the Company's website at http://www.PAREXEL.com. Users should follow the instructions provided to assure that the necessary audio applications are downloaded and installed. A replay of this webcast will be archived on the website approximately two hours after the call and will continue to be accessible for approximately one year following the live event. To participate via telephone, dial (612) 288-0329 and ask to join the PAREXEL Earnings Guidance conference call.

About PAREXEL

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medic
'/>"/>

SOURCE PAREXEL International Corporation Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Olympics of biotechnology has international flavor
2. Traffic data firm navigates international business
3. Catalyst International profit exceeds expectations
4. Lack of broadband hamstrings international videoconferencing
5. 30 days to success: Three simple steps to create your own international startup
6. TEKLYNX International announces new RFID software
7. Ruling enforces international trademark electronic filing requirements
8. Eleftheriou to lead Catalyst International
9. Internet trademark war goes international
10. International eyes drawn to Madisons games research
11. Plexus and SRI International team up to offer medical product development